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ABSTRACT
Differential Receptors for Advanced Glycation End-Products (RAGE) Expression in
Preeclampsia, Intrauterine Growth Restriction and Gestational Diabetes
Kristen Lena Alexander
Department of Physiology and Developmental Biology, BYU
Master of Science
Preeclampsia (PE), intrauterine growth restriction (IUGR) and gestational diabetes
(GDM) increase the risk of maternal and fetal morbidity and mortality. The roles of Advanced
Glycation End-products (AGEs) are already well documented concerning inflammation, hypoxia
and oxidative stress. AGEs bind to its receptor, Receptor for Advanced Glycation End-products
(RAGE), and activate an inflammatory pathway. This pathway alters the efficacy of invasive
trophoblast cells and in the placenta and can result in placental dysfunction. We hypothesized
that the placental dysfunction found in PE, IUGR, and GDM resulted from an over activation of
the RAGE-mediated inflammatory pathway. Using human placental samples, we found that
RAGE protein expression via western blotting was increased in PE and decreased in IUGR while
GDM remained similar to that of control placentas. We then wanted to determine the efficacy of
RAGE activation to alter the invasive nature of invasive cytotrophoblasts cells. We found that
the addition of AGEs to SW71 cells decreases invasion through the activation of JNK and ERK
cellular signaling pathways. Altogether these findings suggest that RAGE activation in
trophoblast cells seems result in insufficient placental pathogenesis causing PE, however the
IUGR and GDM samples we obtained did not seem to have resulted from RAGE activation. We
also found that RAGE activation can alter the ability of invasive trophoblasts to invade, thus
limiting the ability of the placental cells to remodel the maternal spiral arteries. We believe that
further research into specific triggers of IUGR (smoking-induced) and un-treated diabetes could
result in RAGE stimulated placental insufficiency.

Keywords: RAGE, preeclampsia, intrauterine growth restriction, gestational diabetes, AGEs,
pregnancy
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CHAPTER 1: Introduction
Failure to deliver oxygen and nutrients through the placenta to a developing fetus can
result in life threatening conditions for both the fetus and mother. There are a variety of
pregnancy pathologies that can result in placental dysfunction including: preeclampsia (PE),
intrauterine growth restriction (IUGR), and gestational diabetes (GDM). These pathologies affect
the ability of the placenta to transport vital nutrients and oxygen important for fetal development.
In ischemic conditions the ability of maternal spiral arteries to mature allowing greater blood
flow is significantly reduced (Roberts, 2015; Pardi, Marconi, & Cetin, 2002). These pregnancy
pathologies involve a developed hypoxic condition in the uterus/placenta reducing the ability of
the fetus to obtain necessary components for proper growth. Although each pathology is rooted
in ischemia, there are many compounding variables making each disease unique and
complicated. There is not one single pathophysiological disturbance that causes these
pathologies, but a combination of factors that compound to each disease. Because pregnancy
complications are often life threatening to the mother and/or fetus, pathologies such as PE, IUGR
and GDM have been studied profusely. Despite the plethora of knowledge obtained in recent
years, much is left to be understood especially the role of inflammation in ischemic conditions.
Preeclampsia
Preeclampsia is a pregnancy complication that arises in 6-8% of all pregnancies with a
higher occurrence in women with diabetes mellitus, hypertension or a history of preeclampsia
(Sibai, Caritis, & Hauth, 2003). If left untreated, preeclampsia can cause severe morbidity to the
mother and fetus by causing preeclampsia, HELLP syndrome, intrauterine growth restriction,
brain hemorrhage or cardiovascular complications (Naruse, et. al., 2012). Severe preeclampsia
and eclampsia account for 15% of maternal deaths in the United States and significantly higher
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rates in third world countries (Sibai, Caritis, & Hauth, 2003). The phenotype of preeclampsia is
well classified as hypertension combined with proteinuria after 20 weeks gestational age,
however the cause of preeclampsia has not been elucidated. There have been a variety of
pathophysiological processes that have been linked to preeclampsia such as endothelial
dysfunction, oxidative stress, angiogenic and inflammatory factor imbalance and activation of
the receptor for advanced glycation end products (RAGE) (Oliver, et al., 2010). Despite the
plethora of physiological explanations for the development of preeclampsia, there are many
holes of understanding that need to be filled.
Intrauterine Growth Restriction
Intrauterine growth restriction/retardation (IUGR) occurs in 12% of all pregnancies. The
key physiological effect of IUGR is a small-for-gestational age infant accompanied by a small
placenta and a link of the fetus developing coronary heart diseases (Heinonen, Taipale, &
Saarikoski, 2001). A little over three decades ago, it was hypothesized that the small placental
size resulted from decreased migration of trophoblasts when they invade to restructure the
maternal spiral arteries in order to allow greater nutrient and oxygen accessibility to the placenta
and fetus (Pijnenborg, Bland, Robertson, & Brosens 1983). If the maternal spiral arteries are
insufficiently remodeled there is a reduction of blood flow to the placenta compared to controls
(Pijnenborg, Bland, Robertson, & Brosens 1983). The inability for the placenta to transport
necessary nutrients to the fetus results in an undernourished fetus and can lead to fetal death.
Despite the understanding that insufficient trophoblast invasion is utilized in intrauterine growth
restriction, there are no therapeutic targets or methods available to prevent it (Friedman, &
Cleary, 2014). Although the role of trophoblast invasion has been well defined in IUGR, the
cause of trophoblast dysfunction is still being elucidated.
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Gestational Diabetes
In 2014 it was estimated that diabetes affected 387 million people worldwide—which is
8.3% of the global population—with the occurrence of type 2 diabetes mellitus increasing
globally (International Diabetes Federation, 2014). Occurring in 3%-30% of pregnancies,
gestational diabetes is the principal metabolic disorder during gestation (Aires, & de Santos,
2015). Gestational diabetes is glucose intolerance of any degree, which arises (or is diagnosed)
during pregnancy. The maternal glucose intolerance results in an increase in placental weight and
a decrease in fetal/placental weight ratio at birth (Taricco, Radaelli, de Santis, & Cetin, 2003). In
gestational diabetes pathologies, it has been shown that there is an increase in cell proliferation
rate and decrease in apoptosis which results in a larger placenta (Zorn, et al., 2011; Benirschke,
Kaufmann, Baergen, 2006; Belkacemi, Kjos, Nelson, Desai, & Ross, 2013). The immature villi
are unable to successfully transport oxygen and nutrients to the fetus resulting in a hypoxic state
(Benirschke, Kaufmann, Baergen, 2006). Not only is the function of trophoblast cells altered, but
also the trophoblast layers are thicker than normal placentas and have significantly higher lipid
droplets and glycogen (Gewolb, Merdian, Warshaw, & Enders, 1986). Gestational diabetes has
an adverse effect on trophoblast function, but recent studies have demonstrated detrimental
epigenetic changes in the fetus associated with maternal hyperglycemia (Ronald, Tutino,
Lillycrop, Hansen, & Tam, 2015). The underlying mechanism for these pathophysiological
effects are unknown and research is needed to elucidate the causes for these adverse effects.
Receptor for Advanced Glycation End Products (RAGE)
The receptor for advanced glycation end products (RAGE) is a 35kd transmembrane
protein receptor expressed on multiple subtypes of tissues and is known to be part of the
immune-inflammation pathway (Ramasamy, Yan, Herold, Clynes, & Schmidt, 2008). Ligand
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binding of RAGE stimulates multiple cellular signaling cascades: the MAPK activation has been
demonstrated in smooth muscle, myoblasts, osteoblasts, monocytes, and tubular epithelial
myofibroblasts (Lander, Taurus, Ogiste, Hori, Moss, & Schmidt, 1997; Shanmugam, Kim,
Lanting, & Natarajan, 2003; Li, Wang, Huang, Oldfield, Schmidt, Cooper, Lan, 2004; Cortizo,
Lettieri, Barrio, Mercer, Etcheverry, & McCarthy, 2003; Sorci, Ruizzi, Agneletti, Marchetti, &
Donato, 2004). RAGE has also been implicated in a variety of physiological pathologies such as
aging, diabetes, cardiomyopathy, neurodegeneration, nephropathy, retinopathy, rheumatoid
arthritis, chronic kidney disease, inflammation, polycystic ovarian syndrome, preeclampsia, and
obesity (Ramasamy, Vannucci, Yan, Herold, Yan, & Schmidt, 2005; Rojas, Pérez-Castro,
González, Delgado, Romero, & Rojas 2014; Alghasham, & Rasheed, 2014; Singh, Bali, Singh,
& Jaggi, 2014; Merhi, 2013). Not only are there many diseases associated with RAGE, but there
are multiple ligands that can bind and activate RAGE thus perpetrating the disease state such as:
amyloid beta peptide and the family of beta sheet fibrils, amphoterin, S100/calgranulins and
advance glycation end-products (Bucciarelli, et al., 2002, Gugliucci, & Menini, 2014, Bierhaus,
et al., 2005). Advanced glycation end-products (AGEs) are a common ligand for RAGE and
have been studied extensively in pathological conditions. AGEs are produced via the Maillard
reaction when the carbonyl group of a carbohydrate reacts with a primary amino group of a
protein in a non-enzymatic reaction (Brownlee, Cerami, & Vlassara 1988). AGEs are produced
endogenously by our body and can be formed as a byproduct of foods (Poulsen, et al., 2013). In
situations of chronic inflammation, proteins and lipids are modified which also produce AGEs
(Sado, et al., 2011). The regulation of RAGE is dependent on the concentration of receptors in
the membrane of the cell, as well as the concentration of soluble RAGE (sRAGE). The
molecular structure of sRAGE does not contain the transmembrane region; therefore it can bind
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the ligands of RAGE, such as AGEs, but does not activate cellular signaling inflammatory
pathways. Many studies have examined the role of RAGE in pregnancy, specifically with the
concentrations of sRAGE in circumstances of infection, preeclampsia, and IUGR (Oliver, et al.,
2010; Naruse, et. al., 2012). It has been found that AGEs change the formation of the vascular
beds in the placenta which reduces the ability of the placenta to deliver sufficient nutrients and
gas to the fetus (Guedes-Martins, Matos, Soares, Silva, & Almeida, 2013). Despite the research
previously done, there are significantly more questions than answers concerning the effect of
AGEs and RAGE on pregnancy pathologies as well as activation of RAGE in other pregnancy
complications.
Summary of Research
The study outlined in the following chapter is the first to observe RAGE expression and
MAPK activation in preeclampsia (PE), intrauterine growth restriction (IUGR) and gestational
diabetes (GDM). It is also the first to look the effect of AGEs on altering the phenotype of
invasive first trimester trophoblast cells. Because PE, IUGR and GDM can stem from chronic
placental inflammation, we wanted to test if placental insufficiency resulted from a RAGEinduced inflammatory response. If RAGE activation was the culprit behind placental dysfunction
in these pregnancy pathologies, then we could ameliorate the effects of RAGE by the addition of
a small molecule that down-regulates or has competitive binding, thus limiting RAGE activation.
We also wanted to test if RAGE activation in invasive cytotrophoblasts cells could alter the
efficacy of these cells to invade which could possibly result in an inhibition of trophoblast cells
to remodel the maternal spiral arteries. The inability of the placenta to remodel the spiral arteries
results in decreased blood flow to the placenta which can result in decreased nutrients and gas to
the fetus, resulting in a small for gestational age fetus, which can be the case in PE and IUGR.
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However, the activation of the MAPK pathway in trophoblast cells can also result in a
significantly larger placenta which then delivers too much glucose to the fetus, resulting in a
large for gestational age fetus, which occurs often in GDM. Determining the role of RAGE in
altering the invasive properties of trophoblast cells will enable us to seek alternative therapies to
restore vital properties to placental cells.
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Abstract
The Receptor for Advanced Glycation End-Products (RAGE) is a cell surface receptor
implicated in the modulation of diverse inflammatory pathways. Inflammation has been
associated with the development of pregnancy pathologies including preeclampsia (PE),
intrauterine growth restriction (IUGR), and gestational diabetes mellitus (GDM) that can
centrally impact diverse maternal and fetal complications. Our objective was to examine
placental RAGE expression in PE, IUGR, and GDM complications. We hypothesized that
RAGE would be activated in PE, IGUR and GDM. We also hypothesized that RAGE activation
by stimulation of AGEs would result in a decrease of invasion, increase in JNK, ERK and p38
activation as well as an increase in cytokine release. Compared to control placental samples we
observed: 1) a 3.4-fold increase in placental RAGE gene expression during GDM-D, 2) a 2.2fold increase in placental RAGE gene expression during GDM-I, 3) a 2-fold increase of placental
RAGE protein expression in the PE placenta, and 4) a 3-fold decreased of placental RAGE
protein expression in the IUGR placenta. In trophoblast cells exposed to 25 ug of AGEs, a
common RAGE ligand, we observed: 1) decreased trophoblast invasion, 2) a 10-fold increase in
JNK activation, 3) a 8-fold increase in ERK activation, and 4) significantly increased TNF-α and
IL-1β secretion. We conclude that placental RAGE is activated in PE situations and that RAGEmediated inflammation in the trophoblast involves increased TNF-α and IL-1 β secretion through
the activation of ERK and JNK signaling.

Abbreviations:
PE, Preeclampsia
IUGR, Intrauterine Growth Restriction
GDM-I, Gestational Diabetes Mellitus treated with Insulin
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GDM-D, Gestational Diabetes Mellitus treated with diet (GDM-D)
ERK, Extracellular signal-regulated kinases
JNK, c-Jun N-terminal kinases
p38, p38 mitogen-activated protein kinase
TNF-α, Tumor Necrosis Factor Alpha
IL-1β, Interleukin-1 Beta
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Introduction
Inflammation plays a key role in maintaining homeostasis; however exaggerated
inflammation can cause tissue damage and lead to disease (Challis, Lockwood, Myatt, Norman,
& Strauss, 2009). Abnormal inflammation has been associated with various pregnancy
pathologies such as preeclampsia (PE), pre-term birth (PTB), spontaneous abortion and
intrauterine growth restriction (Challis, Lockwood, Myatt, Norman, & Strauss, 2009; Challis,
Lye, Gibb, Whittle, Patel, & Alfaidy, 2001).
Toll-like receptors (TLR) are expressed on the plasma membrane of macrophages and are
associated with inflammatory responses (Challis, Lockwood, Myatt, Norman, & Strauss, 2009).
Previous research has suggested that TLRs may be responsible for enhancing the risk of preterm
birth (Challis, Lockwood, Myatt, Norman, & Strauss, 2009; Challis, Lye, Gibb, Whittle, Patel, &
Alfaidy, 2001). Like TLRs, Receptors for Advanced Glycation End-products (RAGE) are cell
surface pattern recognition receptors detected in many cell types including endothelium, smooth
muscle, macrophages and several specific epithelial cell types (Buckley, & Ehrhardt, 2010;
Warburton, et al., 2005). Of interest, RAGE is also expressed in the human placenta (Holmlund,
et al., 2007). RAGE was initially characterized for its ability to bind to non-enzymatically
glycated macromolecules, advanced glycation end-products (AGEs); however, RAGE ligation
also occurs following the binding of a diversity of ligands of various types (Morbini, Villa,
Campo, Zorzetto, Inghilleri, & Luisetti, 2006). When AGEs bind to receptors, MAP kinases
(MAPK, JNK, p44/42 and p38) and intermediates of the Jak/STAT pathway are activated
(Morbini, Villa, Campo, Zorzetto, Inghilleri, & Luisetti, 2006). While RAGE activation is
implicated in inflammation and cell migration, the expression of RAGE is relatively low in most
physiological settings. Interestingly, inflammatory responses up regulate RAGE and enhance its
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activation culminating in increased activity of several MAPKs and NF-κB mobilization to the
nucleus (Xie, Mendez, Mendez-Valenzuela, & Aguilar-Hernandez, 2013). NF-κB is then capable
of coordinating augmented expression and secretion of a variety of inflammatory responserelated molecules such as tumor necrosis factor α (TNFα), interferon γ (INF-γ) and interleukin 6
(IL-6) (Xie, Mendez, Mendez-Valenzuela, & Aguilar-Hernandez, 2013).
RAGE is up regulated in disease states such as diabetes, lung fibrosis, acute respiratory
distress syndrome (ARDS), polycystic kidney disease, chronic obstructive pulmonary disease
(COPD), and in the myometrium of women affected with preeclampsia (Bohlender, Franke,
Sommer, & Stein, 2005; Cooke, Brockelsby, Baker, & Davidge, 2003; Ferhani, et al., 2010; He,
et al., 2007; Nakamura, et al., 2011; Oliver, et al., 2011; Park, Seo, & Park, 2010; Robinson,
Johnson, Bennion, & Reynolds, 2012; Wu, Merrilees, Young, & Black, 2011). In conditions
associated with abundant RAGE ligands, positive feedback loops may also exacerbate persistent
inflammation observed in chronic disease conditions (Schmidt, Yan, Yan, & Stern, 2001). While
RAGE has been implicated in a few studies involving PE, little research has been conducted that
involves RAGE and other pregnancy pathologies.
The placenta often functions insufficiently in terms of fulfilling the needs of the
developing fetus during pregnancy complications. Accordingly, a properly functioning placenta
is critical for pregnancy success. Specifically, the placenta is vital for fetal development as it
mediates gas and nutrient exchange between mother and fetus. During implantation, the placental
cytotrophoblasts differentiate and invade into the uterine endometrium and myometrium and
remodel the uterine spiral arteries to become low resistant, high capacity vessels (Arroyo, &
Winn, 2008; Pijnenborg, et al., 1991; Reuvekamp, Velsing-Aarts, Pouline, Capello, & Duits,
1999; Zhou, Damsky, & Fisher, 1997). The remodeling of these arteries allows increased oxygen
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and nutrient exchange (Arroyo, & Winn, 2008; Pijnenborg, et al., 1991; Reuvekamp, VelsingAarts, Pouline, Capello, & Duits, 1999; Zhou, Damsky, & Fisher, 1997). In many pregnancy
pathologies, the trophoblast remodeling is insufficient and the placenta is unable to sufficiently
nourish the maturing fetus (Saito, & Nakashima, 2014). The processes that lead to decreased
placental function are multifactorial and may vary between different pathologies as well as
among patients. Given the role of RAGE in diseased inflammatory tissues, our initial goal was to
identify the expression profile of RAGE in several of the most common placental pathologies.
Through the identification of RAGE expression, impaired invasion, and inflammatory signaling,
our research suggests a role for RAGE and its activation in the biology of placental trophoblast
cells.
Material and Methods

Human Placental Tissues
Placental biopsies and paraffin embedded placental tissues slides for PE, IUGR, GDM-I
(gestational diabetes mellitus treated with insulin), GDM-D (gestational diabetes mellitus treated
with diet) and control placenta were purchased from the Research Center for Women’s and
Infant’s Health BioBank, Ontario, Canada. Placentas were collected shortly after delivered either
vaginally or by C-section. Ten samples were analyzed for each group. PE was confirmed by
increased maternal blood, pressure, and increased proteinuria. IUGR placentas were confirmed
by ultrasound showing placental insufficiency with uterine Doppler and absent end diastolic flow
(AEDV). IUGR samples also came from patients with an estimated fetal weight below the 10th
percentile. Sample demographics are shown in Table 1.
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Real Time PCR
Real time PCR was performed to determine gene activation of the RAGE receptor in the
placenta of normal and complicated pregnancies. cDNA was synthesized using Oligo (dT) and
SuperScript II Reverse Transcriptase (both from Invitrogen by Life Technologies, Carlsbad, CA)
by following the protocol suggested by the manufacturer. RT-PCR was performed using SsoFast
EvaGreen Supermix (Bio-rad Laboratories, Hercules, CA), which contains a cocktail of all
necessary components excluding primers and templates. Sso7d-fusion polymerase was used as
the enzyme. Primers for RAGE (Fwd- ACTACCGAGTCCGAGTCTACC, RevGTAGCTTCCCTCAGACACACA), were utilized with 18S primers (Fwd.GGGAGGTAGTGACGAAAAATAACAAT, Rev.-CCCTCCAATGGATCCTCGTT) as a
baseline control for the various experiments. Results were tested for significance against control
placentas. Cycling conditions were as follows: 95°C for 30 seconds; 95°C for 5 seconds; 60°C
for 30 seconds; melt curve, 65°C for 2 seconds and 95°C for 5 seconds.

Immunofluorescence
IF was performed on paraffin embedded placental samples. In summary, slides were dewaxed, washed in a 1x Tris buffer solution (TBS), and blocked with Background Sniper (Biocare
Medical, Concord, CA) for one hour. This was followed by incubation overnight with a primary
RAGE antibody (Cell Signaling Technology, Danvers, MA), or Cytokeratin 7 (Dako,
Carpinteria, CA,). Slides were then incubated for 1 hr with donkey anti rabbit TR or donkey antmouse TR (Biocare Medical, Concord, CA). 4’, 6-diamidino-2-phenylindole, dihydrochloride
(DAPI) was used for counterstaining prior to mounting with glass coverslips. Slides were
viewed using a Texas Red excitation and emission filter.
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Trophoblast Cell Culture
The first-trimester cytotrophoblast cell line Swan71 (SW71) was used for cytotrophoblast
experiments. SW71 cells were cultured in RPMI medium (Mediatech, Manassas, VA)
supplemented with 10% fetal bovine serum (FBS) and 1%penicillin and streptomycin.

Cell Treatments
SW71 cytotrophoblast cells were incubated in normal culture medium in a 6 well plate.
At 50% confluency cells were cultured overnight at 2% serum to create quiescence. Cell
cultures were exposed to media supplemented with 25 μg/ml of advanced glycation end products
((Carboxymethyl)-lysine-BSA, Circulex) or untreated media for 24 hours. After treatment, cell
medium was collected and stored at -20°C for ELISA, and cells were lysed and stored at -80°C
for molecular studies.

Real-Time Cell Invasion Determination
Real-time invasion of SW71 cells was performed using an xCELLigence RTCA DP
(Real-Time Cell Analysis Dual Plate) instrument as previously described.[23] Briefly, cells were
plated in the top chamber at a concentration of 20,000 cells/well in 2% FBS RPMI in a total
volume of 100 μL in the presence or absence of 25 μg/ml of AGEs. The bottom chamber wells
were filled with 160 μL of 10% FBS RPMI. The cells were then place in the RTCA DP
instrument, and invasion readings were taken every 15 min for the next 24hr.

18

Western Blot Analysis
Western blot analysis was used to assess the expression of RAGE and a collection of cell
signaling proteins in control and diseased placenta. Cell lysates (50 μg) were separated on 4–
12% Bis-Tris gel SDS-PAGE and transferred to nitrocellulose membranes. Membranes were
incubated with antibodies against RAGE, and phospho- and total ERK, p38 and JNK proteins
(all from Cell Signaling Technology). Membranes were then incubated with a secondary
horseradish peroxidase (HRP)-conjugated antibody for one hour at room temperature. The
membranes were incubated with ECL substrate, and the emission of light was detected using xray film. To determine loading consistencies, each membrane was stripped and re-probed with an
antibody against mouse β-actin (Sigma Aldrich, St. Louis, MO). Expression levels of the
proteins were quantified by densitometry normalized to β-actin expression and changes in the
expression of the various targets were compared to the untreated controls.

Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA was used to assess the concentration of tumor necrosis factor alpha (TNF-α) and
interleukin 1 beta (IL-1β) cytokines secreted by trophoblast following treatment with AGEs.
Briefly, media was removed before cell lysis, and equal volumes of cell culture media (50 ul)
were assessed in each experimental group for concentrations of cytokines in triplicate using a
TNF-α ELISA kit (Ray Biotech, Norcross, GA) or an IL-1β ELISA kit (R&D Systems) as
directed by the manufacturer.
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Statistical Analysis
Comparisons of the following endpoints were made between control and treated samples:
ELISA, mRNA, and protein levels of RAGE, p-JNK, p-ERK. All data were assessed for
normality and treatment effects were determined by using Mann-Whitney test, with p<0.05
considered significant.
Results
Placental (RAGE) Expression Profile
While RAGE is notably expressed in lung and immune tissues, basal expression of the
receptor is also detected in several systemic tissues as well (Schmidt, Yan, Yan, Stern, 2001).
We initially evaluated the transcriptional activation of the RAGE gene in control placentas and
those affected by PE, IUGR and GDM. When compared to the control placenta, we discovered
no significant differences in the levels of RAGE mRNA in the PE and IUGR placenta (Figure
2.1A). In contrast, RAGE mRNA expression was significantly decreased in the GDM-D (3.4fold; p<0.0007) and GDM-I (2.2-fold; p<0.004) placenta (Figure 2.1A). We next investigated
protein levels of placental RAGE in the control and pathological placentas. Interestingly we
observed that placental RAGE protein expression was significantly increased (2-fold; p<0.03) in
the PE placenta when compared to controls (Figure 2.1B). In contrast there was a significant
decrease in RAGE expression (3-fold; p<0.02) in IUGR samples when compared to controls
(Figure 2.1B). No differences in RAGE expression were observed when comparisons were made
between the control and GDM placentas. We next performed qualitative immunofluorescence for
RAGE in order to determine whether altered RAGE expression in affected placentas localized to
trophoblast cells. RAGE was notably present in the villi trophoblast of control placenta (Figure
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2.2). When compared to controls, RAGE was increased in the villi trophoblast of the PE
placenta while decreased in placentas identified as IUGR, GDM-D, and GDM-I (Figure 2.2).

RAGE in Invasive Trophoblast Cells
A hallmark of PE placenta is decreased invasion of trophoblast cells. We next
investigated if, like the villi trophoblast, invasive trophoblast cells expressed RAGE. Western
blot experiments showed expression of RAGE in invasive trophoblast cells (Figure 2.3A). To
determine the mechanistic effects of R activation in the invasion of trophoblast cells, we treated
cells with (carboxymethyl)-lysine-BSA (25 ug/ml), a type of AGEs which are a common RAGE
ligand, for 24 hours in culture. Trophoblast cell invasion was significantly decreased (1.5-fold;
p<0.05) after 24 hour exposure (Figure 2.3B). In terms of RAGE signaling, our in vitro
experiments resulted in a significant increase in the activation of JNK (10-fold; p<0.006) and
ERK (8.0-fold; p<0.002) following the addition of AGEs (Figure 2.4A-B). In contrast, the
addition of AGEs was not sufficient to induce an appreciable expression of active p38.

AGEs-RAGE Ligation and Cytokine Release
The activation of RAGE following AGEs incubation has been shown to induce the
release of cytokines such as TNF-α and IL1B; however, no such studies have been performed to
date in placental cells (Schmidt, Yan, Yan, & Stern, 2001). RAGE activation by AGEs induced
increased synthesis and secretion of TNF-α (1.8-fold; p<0.05) and IL-1β (1.3-fold; p<0.05) by
invasive trophoblast cells in culture (Figure 2.5A-B).
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Discussion
In the present study, we assessed RAGE expression in the placenta of patients affected by
PE, IUGR, and GDM and evaluated signaling molecules in a cytotrophoblast cell line exposed to
RAGE ligands. The biology of RAGE has been a centerpiece of inflammation research for
several years and despite clear functions in the pulmonary apparatus, focus has also turned to
several non-pulmonary tissues. Notwithstanding a more inclusive research approach, clarifying
potential functions in placentas from normal and complicated pregnancies has been limited. A
role for RAGE in normal placentation is supported by research that identified RAGE localization
to the developing human trophoblast (Konishi, et al., 2004). Specific placental roles for RAGE
have been enigmatic, but a plausible function relates to RAGE activation during the coordination
of apoptosis (Konishi, et al., 2004).
In relation to the diseased placenta, our research confirms previous studies that identified
increased RAGE levels in the serum of patients with severe preeclampsia, and in patients with
gestational diabetes but studies centered on its expression during IUGR are still inadequate
(Oliver, et al., 2011; Tang, Qin, Xie, & He, 2015). Interestingly, RAGE mRNA transcription was
not different in placentas affected with PE or IUGR; however, RAGE protein was disparately
regulated leading to elevated RAGE protein in PE placentas and significantly decreased protein
availability in the IUGR placenta. These findings suggested differential posttranscriptional
regulation of RAGE in cases of these diseases. Such posttranscriptional and posttranslational
regulation of RAGE has already been presented, particularly in cases of defective immune
responses and apoptosis (Brune, et al., 2013; Grimm, Ott, Horlacher, Weber, Hohn, & Grune,
2012). While no differences in RAGE expression were observed in the GDM placenta, our
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results are potentially impacted by specific treatment regimen involving insulin or diet, two
modalities known to diminish diabetic symptoms (Magon, & Seshiah, 2011; Poomalar, 2015).
Elevated RAGE detection in the PE placenta also corroborates a recent discovery that
soluble RAGE is increased in the serum of PE patients (Oliver, et al., 2011; Germanova, et al.,
2010). As observed in other disease states, circulating soluble RAGE may provide evidence of
RAGE-mediated coping mechanisms in the inflammatory profile of PE (Basta, Del Rurco,
Navarra, & Lee, 2015; Benjyo, Smarason, Redman, Sims, & Conrad, 2001; Cai, et al., 2015;
Ciccocioppo, et al., 2015; Lee, et al., 2015; Redman, & Sargent, 2003). Studies have previously
demonstrated RAGE immunoreactivity in both the syncytiotrophoblast and cytotrophoblast of
normal pregnancies. Our research goes further by localizing RAGE to villi and robust
expression of RAGE in the villi of PE placentas provides important insight into probable RAGEmediated effects that warrant further investigation.
The in vitro assessment of invasive trophoblasts exposed to AGEs resulted in the
implication of RAGE signaling as a modulator of placental apoptosis, hindered invasion, and
inflammatory cytokine elaboration observed in complicated pregnancies (Lunghi, Ferretti,
Medici, Bionidi, & Vesce, 2007). In fact, our findings confirm elevated inflammatory responses
and compromising apoptosis are both mediated, at least in part, by RAGE signaling (Konishi, et
al., 2004). Apoptosis and hindered invasion are characteristics that distinguish placentas of
complicated pregnancies. Accordingly, a higher apoptotic index in cells required in the
establishment of villi, coupled with decreased invasion, suggested AGEs-RAGE interactions
may assist in the derivation of compromised placentas. Much like the administration of
lipopolysaccharide (LPS) and the activation of TLRs in a rat model of PE, the availability of
RAGE ligands at critical periods of placentation may deregulate immune responses at the
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maternal-fetal interface contributing to poor early placentation (Xue, et al., 2015). It is also likely
that placental abnormalities stem from the elaboration of cytokines such as TNF-α and IL-1β
following the activation of RAGE signaling. TNF-α secretion by trophoblasts has previously
been documented to threaten pregnancy outcome, and it likely cooperates with an array of local
cytokines including IFN-γ, IL-6 and IL-1β that exacerbate PE-related inflammatory responses
(Diaz, et al., 2009; Noyola-Martinez, et al., 2013). Taken together, the current research opens the
door to an important pro-inflammatory signaling program that when targeted, may be effective in
ameliorating obstetrics complications.
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Table 2.1: Demographical Data for Human Placenta Samples. Groups were analyzed for
statistical significance (p < 0.05) using the Kruskal-Wallis test. There was no difference in
maternal age. PE and IUGR groups were statistically lower from control in gestational and fetal
weight.

Maternal Age
Gestational Age (wks)
Fetal Weight (g)
% C-section /Vaginal

Control
34±1.6
39±0.07
3498±59
90%/10%

PE
36±2.2
32±1.3
1893±344
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IUGR
30±1.6
32±0.7
1005±47.3

GDM-D
33±1.5
38±0.3
3245±151

GDM-I
35±1.4
39±0.8
3453±217

P value
0.326
0.007
0.004

Figure 2.1: RAGE Profile in Pregnancy Pathologies. Real time PCR showed deceased RAGE
gene transcription (p<0.004, n=6) in GDM-D and GDM-I placentas when compared to controls
(A). Western blot analysis showed increased placental RAGE protein expression during PE
(p<0.03, n=6) while there was a significant decreased in RAGE expression in the IUGR placenta
when compared to controls.
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Figure 2.2: RAGE Immunofluorescence in Pregnancy Pathologies. RAGE levels were elevated
in preeclampsia affected placenta samples. Immunofluorescence (IF) staining for RAGE in
placental tissue samples; Control, Preeclampsia (PE), Intrauterine Growth Restriction (IUGR),
Gestational Diabetes treated with diet (GDM-D), Gestational Diabetes treated with Insulin, CK7
(for trophoblasts localization) and negative control. Immunofluorescence confirmed increased
RAGE in the villi trophoblast in PE placentas and decreased expression in the villi trophoblast of
IUGR placenta. 20x scale.
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Figure 2.3: AGEs-induced Alteration of Trophoblast Invasion. Immunoblotting showed
expression of RAGE in invasive trophoblast cells (A). Invasive properties of these cells were
reduced (p<0.05, n=6) when RAGE was activated by treatment with 25 μg/ml of AGEs.

32

Figure 2.4: AGEs-induced MAPK Regulation. JNK was activated (p<0.006, n=6) in invasive
trophoblast cells when treated with 25 μg/ml AGEs for 24 hours (A). Similarly, ERK was
significantly activated (p<0.002; n=6) in treated trophoblast cells (B).
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Figure 2.5: AGEs-induced Cytokine Release. TNF-α and IL-1β release by trophoblast cells
treated with AGEs (n = 6). There was an increase (p<0.05) in the release of the inflammatory
cytokines TNF-α and IL-1β when RAGE was activated by AGEs in trophoblast cells (A-B).
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CHAPTER 3: General Discussion and Future Directions
Our data from the previous chapter reinforce other studies implicating RAGE as a mediator to
the pathogenesis of preeclampsia. It has been previously shown that the AGEs-RAGE system is up
regulated in preeclampsia and can contribute to vascular dysfunction due to oxidative stress (Chekir, et
al., 2006). It had been hypothesized that RAGE is increased in preeclampsia due to a slurry of hypoxia,
oxidative stress, and chronic inflammation (Sado, et al., 2011). What has not been demonstrated before
our study is an in-depth examination of RAGE expression and the MAPK downstream signaling
cascade. We studied this pathway and were able to demonstrate that it is through activation of the
MAPK pathway that we see decreased invasion leading to placentation failure.
The first point presented in our research analyzes the RAGE expression levels in a variety of
pregnancy pathologies: preeclampsia (PE), intrauterine growth restriction (IUGR) and gestational
diabetes treated with insulin or diet (GDM-I or GDM-D respectively). Previous research has
demonstrated that inflammation during pregnancy is key to pregnancy pathologies (Girard, Heazell,
Derricott, Allan, Sibley, Abrahams, & Jones, 2014). They found that serum levels of inflammatory
markers in the mother represented biomarkers of placental inflammation. Because RAGE is associated
with the inflammatory pathway, we investigated RAGE expression in PE, IGUR, GDM-I and GDM-D.
We found that RAGE protein levels are increased in conditions of PE and decreased in conditions of
IUGR although the mRNA levels remain unchanged. These conclusions enhance the research previously
published that sRAGE levels are decreased in pregnant women but the levels are significantly higher in
women with severe preeclampsia suggesting that the RAGE system is activated in severe preeclampsia
(Oliver, et al., 2010). Because no previous research has been done with regards to IUGR, this is novel
information that the mRNA levels are similar to PE, but protein expression is decreased even though
there is similar trophoblast dysfunction in IUGR. We have shown through protein and mRNA analysis
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that RAGE expression is higher in women with PE. We have also demonstrated that the increase of
RAGE is centralized to the trophoblasts in the placenta. This information supports our hypothesis that
women with PE have higher RAGE expression levels. However, we found that in GDM-I and GDM-D
the mRNA levels are significantly lower, but the protein levels are unchanged compared to the control
placentas. Because the gestational diabetes patients were undergoing treatment of either insulin or diet,
we believe that the treatment of the diabetic symptoms could alleviate the inflammatory pathway and
could potentially be the reason why RAGE mRNA levels were decreased (Magon, & Seshiah, 2011;
Poomalar, 2015). To the best of our knowledge, this is the first study examining the expression of
RAGE in IUGR and GDM. We have found that although RAGE is increased in PE, it is decreased in
IUGR and not significantly changed in GDM-I or GDM-D. More studies need to be done to identify the
RAGE expression in GDM patients not undergoing treatment as well as more experiments to understand
what is causing the trophoblast dysfunction in IUGR if RAGE is not up regulated.
The second conclusion reached in the previous chapter is that the addition of Advanced
Glycation End-Products (AGEs) to stimulate RAGE expression is sufficient to decrease cell invasion.
AGEs are a product of the Maillard reaction and results in a carbonyl reacting with an amino group of a
protein (Brownlee, Cerami, & Vlassara, 1988). This reaction occurs endogenously, in oxidative stress,
and is even produced when some foods are heated (Poulsen, Hedegaard, Andersen, Courten, Bügel,
Nielsen, Skibsted, & Dragsted, 2013). AGEs are abundant in our lifestyle and are known to be a ligand
to RAGE (Bierhaus, Humpert, Morcos, Wendt, Chavakis, Arnold, Stern, & Nawroth, 2005). When we
stimulated RAGE by adding its ligand, we saw a markedly decreased rate of invasion in first trimester
trophoblast cells. Because PE and IUGR develop when proper placentatation fails (usually due to
insufficient invasion of the trophoblasts), this further substantiates the theory that RAGE activation is a
component in these pregnancy pathologies (Pijnenborg, Bland, Robertson, & Brosens, 1983). Not only
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did we find that AGEs stimulation decreases invasion, but we found that it occurs through the MAPK
pathway.
In order to further understand the role of RAGE in PE, IUGR and GDM we investigated the
protein signaling cascade activated by RAGE. When ligands bind to R, multiple cellular signaling
cascades are stimulated; we focused specifically on MAPK pathway activation. After AGEs stimulation,
we saw that the trophoblast cells had a remarkable increase in JNK and ERK activation while p38 was
undetectable. The production of AGEs resulted in oxidative stress, when you mimic oxidative stress in
trophoblast cells by adding hydrogen peroxide, there is an increase in JNK, p-38 and ERK expression
(Tang, Liang, Oian, Lin, Du, Li, & Li, 2014). This is similar to our findings that JNK and ERK are
activated when AGEs stimulates the expression of RAGE. Increased regulation of JNK results in
dimerization and the ability of JNK to regulate gene transcription in the nucleus (Kyriakis, 1999).
Through gene regulation, JNK activates physiological changes such as apoptosis, inflammation,
tumorigenesis and cell migration. ERK is a similar kinase as JNK; once activated, ERK can translocate
into the nucleus and regulate transcription, or it can target proteins in the cytosol. ERK activation
generally results in a variety of effects such as adhesion, proliferation, differentiation, and survival
(Huttenlocher, et. al, 1998). Because we notice that AGEs stimulated RAGE activation triggers the JNK
and ERK cellular signaling pathways to be up regulated, we can hypothesize that it is through RAGE
activation that the trophoblast cells lose their innate ability to migrate and invade thus resulting in
placental dysfunction.
After having confirmed that RAGE expression is increased after AGEs stimulation in trophoblast
cells and having found that it activates the JNK and ERK signaling pathways, we looked at the release
of cytokines from the trophoblasts indicating the cells are sending inflammatory signals. We found that
both TNF-α and IL-1β levels are increased after RAGE activation. This demonstrates that the cells
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recognize the inflammatory state they are in and actively communicate with surrounding cells to
stimulate an inflammatory response tissue wide.
This research has broad implications on the prevention of pregnancy pathologies. Because
RAGE activation initiates an inflammatory pathway that can result in trophoblast dysfunction, if we can
prevent the activation and stimulation of RAGE then we could alleviate the root cause of ineffective
placentation and restore function of trophoblast cells to modify maternal spiral arteries. By
understanding the AGEs-activated RAGE signaling cascade, we will be able to produce novel small
molecules to decrease RAGE activation.
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